Actinogen R&D tax incentive rebate of $10.8M lifts pro-forma cash to $21.9M
Actinogen Medical (ASX: ACW) has received a research and development tax incentive (RDTI) rebate of $10,838,793 (including interest) from the Australian Tax Office (ATO) for the 2026 financial year, announced on 26 October 2026.
The company confirmed a pro-forma quarter end cash position of $21.9 million, with no debt. The balance sheet update comes as Actinogen approaches topline final results from its pivotal phase 2b/3 Xanamem Alzheimer’s trial, expected in mid-November.
Dr Steven Gourlay, CEO and Managing Director, is the investor contact named in the announcement.
When big ASX news breaks, our subscribers know first
How the rebate flows through to the balance sheet
Actinogen had borrowings from Endpoints Capital of $4.3 million as an advance against its FY26 RDTI. That loan, plus interest, has been repaid in full from the gross rebate, leaving the company with no debt.
Net proceeds received by the company totalled $5,993,390. Combined with the previously announced cash balance, this produces the pro-forma figure below.
| Item | Amount | Note |
|---|---|---|
| Gross RDTI rebate (including interest) | $10,838,793 | Received from the ATO for the 2026 financial year |
| Endpoints Capital borrowings repaid | $4.3 million, plus interest | Advance against FY26 RDTI |
| Net proceeds received | $5,993,390 | Received by the company |
| Previously announced cash balance | Approx. $15.9 million | As at 30 September 2026 |
| Pro-forma quarter end cash position | $21.9 million | No debt |
Why the RDTI matters to biotech investors
The RDTI is an Australian federal government program under which companies receive cash rebates for eligible research and development expenditure by way of refundable tax offset. The source describes it as “an important part of the Company’s ongoing sources of funds”.
- What it is: a cash rebate delivered through a refundable tax offset.
- Who gets it: companies with eligible research and development expenditure.
- Why it is non-dilutive: the rebate is paid by the government rather than raised through issuing new shares.
What the cash is backing: the XanaMIA phase 2b/3 trial
The XanaMIA phase 2b/3 trial is the pivotal study whose topline final results are expected in mid-November 2026. Key design features include:
- 247 patients with mild to moderate Alzheimer’s disease and progressive disease, confirmed by an elevated level of the pTau181 protein biomarker in blood
- A double-blind, 36-week, placebo-controlled design, with patients receiving Xanamem 10 mg or placebo once daily
- A primary endpoint of CDR-SB (Clinical Dementia Rating scale, Sum of Boxes)
- Conduct in Australia and the US, with the trial now closed to participant recruitment
- Passage of an independent Data Monitoring Committee safety and efficacy futility review
The XanaMIA-OLE open-label extension offers up to 25 months of treatment, with all participants receiving active Xanamem 10 mg once daily. It commenced in March 2026 and is open to all former and current participants in the XanaMIA trial.
The earlier XanaCIDD phase 2a depression trial in 167 patients reported results in August 2024. It showed clinically and statistically significant benefits on depression symptoms, with positive effects on the MADRS scale and the PGI-S. The company states this further validated the cortisol control mechanism for the Xanamem 10 mg oral daily dose.
About Xanamem
Xanamem is a once-a-day pill designed to control elevated cortisol in the brain by inhibiting the cortisol synthesis enzyme 11β-HSD1. The company has studied this inhibition in more than 500 volunteers and patients across eight clinical trials.
Xanamem is an investigational product and is not approved for use outside of a clinical trial by the FDA or by any global regulatory authority.
What happens next for Actinogen
The announcement points to one dated event ahead:
- XanaMIA phase 2b/3 topline final results: expected in mid-November 2026, with Actinogen responsible for reporting. The results will show how Xanamem performed against the CDR-SB primary endpoint in Alzheimer’s disease.
For investors, the rebate leaves Actinogen with a pro-forma quarter end cash position of $21.9 million and no debt heading into that readout.
Don’t Miss the Next Healthcare Breakout
Join 20,000+ investors getting FREE breaking ASX news within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to receive healthcare and biotech updates the moment market-moving announcements land, so you stay ahead of the market.